SCHEMBL26315916

SCHEMBL26315916

CCCOCCOCCOCCOCCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
CA12 O43570 6/20 0.45
CA1 P00915 6/20 0.45
CA2 P00918 5/20 0.45
CA9 Q16790 5/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
IDO1 P14902 1/20 0.43
EPHX1 P07099 1/20 0.42
BCHE P06276 1/20 0.41
CNR2 P34972 1/20 0.41
EPHX2 P34913 1/20 0.41
ADRB2 P07550 1/20 0.41
HTR1A P08908 1/20 0.41
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14258531 1.00 TDP1 (0.50) TDP1MEN1KMT2AGAACA12
SCHEMBL22862014 1.00 TDP1 (0.50) TDP1MEN1KMT2AGAACA12
SCHEMBL47067 1.00 TDP1 (0.50) TDP1MEN1KMT2AGAACA12
SCHEMBL18591853 1.00 TDP1 (0.50) TDP1MEN1KMT2AGAACA12
SCHEMBL18365026 1.00 TDP1 (0.50) TDP1MEN1KMT2AGAACA12
SCHEMBL10072751 0.98 TDP1 (0.51) TDP1MEN1KMT2AGAACA12
SCHEMBL12885084 0.93 TDP1 (0.56) TDP1MEN1KMT2AGAACA12
SCHEMBL22276641 0.93 TDP1 (0.56) TDP1MEN1KMT2AGAACA12
SCHEMBL22276648 0.93 TDP1 (0.56) TDP1MEN1KMT2AGAACA12
SCHEMBL29975063 0.91 CA12 (0.46) TDP1MEN1KMT2AGAACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE BET1, BRD4, PHKB TDP1 2942/4885MEN1 1351/4885KMT2A 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.